TRLs and Funding: Your Guide to Paying for Innovation.

Investors and grant bodies keep asking startups the same question in different words: how far is this from working in the real world? Technology Readiness Levels are the shorthand for that answer. Place your technology accurately on the scale and you'll waste much less time pitching the wrong money to the wrong people.

TRLs came out of NASA in the 1970s and now sit at the centre of how Innovate UK, the European Commission, and most deep tech investors talk about maturity. There are nine levels, running from an idea on paper to a product that's been proven in service.

The nine levels

Software-heavy businesses often move through the middle levels in weeks rather than years, which is why a pure SaaS company rarely talks in TRL language at all. A fusion reactor or a new battery chemistry might spend a decade between TRL 4 and TRL 7. The scale matters most when the science risk is real and expensive to retire.

How TRLs line up with funding rounds

There's no perfect mapping, and anyone who tells you TRL 6 always equals a Series A is selling something. But the rough correspondence is useful because it tells you what a funder expects to see for their money.

The point of the table is the direction of travel, not the exact boundaries. What you're really doing at each round is buying yourself the next level of proof.

Which investors care at which level, and why it depends on your business

The type of investor interested in you at TRL 4 depends heavily on what you're building.

If you're a deep tech or hardware company, TRLs 1 to 4 are mostly grant and angel territory. Very few institutional VCs will write a cheque when the core technology still might not work, because the science risk is too high and the timelines are too long for a standard ten-year fund. The investors who do engage early tend to be specialists: funds like IQ Capital, Amadeus, or Octopus Ventures in the UK, university venture arms, and angel syndicates with a technical background who understand what they're looking at. Deep tech seed funds increasingly bridge TRL 4 to 6, betting that lab validation will translate to a relevant environment.

If you're a software company, the whole frame shifts. A generalist seed VC cares far less about where your technology sits on a readiness scale and far more about early users, retention, and whether people will pay. The TRL model was built for physical systems, so a B2B SaaS founder pitching "TRL 5" to a generalist fund will usually get a confused look. Save that language for grant applications and for investors who specialise in hard technology.

For biotech and therapeutics, readiness maps onto clinical phases and regulatory milestones more than TRLs, and the investor base is specialised from day one. For climate and energy hardware, expect a mix of grant funding, specialist climate funds, and eventually corporate and infrastructure money once you're demonstrating at TRL 7 and above, because those investors want to see the thing running before they commit real capital.

The general rule holds across all of them: the earlier and more technical the risk, the more you'll lean on grants and specialists, and the later and more commercial the risk, the more generalist and growth-focused the money becomes.

UK grant funding, and where it fits on the scale

Grants are the natural fit for the lower TRLs precisely because that's where private capital is most reluctant. Non-dilutive money that pays for de-risking science is a strong deal for a founder, so it's worth knowing the main UK routes.

Innovate UK is the anchor. Its Smart Grants competitions fund novel, high-impact innovation across any sector, typically awarding somewhere in the tens of thousands up to around £500,000, and they expect your project to be past pure research with a credible route to market. That maps roughly to TRL 3 through 7 depending on the competition. Innovate UK runs these on a rolling basis, so check the Innovation Funding Service for what's currently open, since the specific competitions change through the year.

Earlier than that, ICURe helps researchers test whether there's a market for lab-stage technology, which suits TRL 2 to 4. Innovate UK also offers Innovation Loans for later-stage projects that are closer to commercialisation but still too risky for a bank, useful around TRL 6 to 8.

Beyond Innovate UK, the British Business Bank underpins a lot of the ecosystem through programmes like the Enterprise Capital Funds and the Regional Angels Programme, though it mostly channels money via other funds rather than to you directly. Sector and regional grants exist through the Catapult network and local growth bodies, and if you're a university spinout, your institution's tech transfer office and proof-of-concept funds are often the fastest early money.

Two things founders routinely underuse. First, R&D tax relief, which isn't a grant but refunds a chunk of qualifying development spend and effectively extends your runway at every TRL. Second, the tax-advantaged investment schemes: SEIS and EIS don't pay you, they make you more attractive to angels by giving them generous income tax relief for backing early, risky companies. SEIS is aimed at very young companies, letting one raise a capped amount in its first years, and EIS covers larger raises after that. The exact limits move with each Budget, so confirm the current figures with HMRC or your accountant before you build them into a pitch. For most early-stage UK founders, having SEIS or EIS advance assurance in hand makes an angel conversation much easier.

What to actually do with this

Work out where you sit, then match the money to the level. Grants and angels for the early, science-heavy work. Seed and Series A capital once you've got a prototype proving itself in something like the real world. Generalist VCs when the risk you're retiring is commercial rather than technical.

The most common mistake isn't picking the wrong TRL. It's pitching a TRL 3 company to investors who only fund TRL 7, then concluding the market doesn't get it. It does. You're just knocking on the wrong door.